Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation

被引：40

作者：

Goyama, S ^{[1
]}

Kanda, Y ^{[1
]}

Nannya, Y ^{[1
]}

Kawazu, M ^{[1
]}

Takeshita, M ^{[1
]}

Niino, M ^{[1
]}

Komeno, Y ^{[1
]}

Nakamoto, T ^{[1
]}

Kurokawa, M ^{[1
]}

Tsujino, S ^{[1
]}

Ogawa, S ^{[1
]}

Aoki, K ^{[1
]}

Chiba, S ^{[1
]}

Motokura, T ^{[1
]}

Shiratori, Y ^{[1
]}

Hirai, H ^{[1
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan

来源：

LEUKEMIA & LYMPHOMA | 2002年 / 43卷 / 11期

关键词：

hepatitis B virus; reverse seroconversion; hematopoietic stem cell transplantation; immunosuppression;

D O I：

10.1080/1042819021000033042

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatitis B virus (HBV) reactivation in patients previously positive for hepatitis B surface antibody (HBsAb), so-called reverse seroconversion, has been considered to be a rare complication after hematopoietic stem cell transplantation (HSCT). We experienced two patients who developed reverse seroconversion among nine who were HBsAb positive and Hepatitis B core antibody (HBcAb) positive before HSCT; one after autologous bone marrow transplantation (BMT) and another after allogeneic peripheral blood stem cell transplantation (PBSCT). We reviewed the literature and considered that reverse seroconversion of HBV after HSCT is not uncommon among HBsAb positive recipients. The use of corticosteroids, the lack of HBsAb in donor, and a decrease in serum HBsAb and HBcAb levels may predict reverse seroconversion after HSCT.

引用

页码：2159 / 2163

页数：5

共 13 条

[1]

CHEN PM, 1993, INT J HEMATOL, V58, P183

[2] CHANGING OF HEPATITIS-B VIRUS MARKERS IN PATIENTS WITH BONE-MARROW TRANSPLANTATION [J].

CHEN, PM ;

FAN, S ;

LIU, CJ ;

HSIEH, RK ;

LIU, JH ;

CHUANG, MW ;

LIU, RS ;

TZENG, CH .

TRANSPLANTATION, 1990, 49 (04) :708-713

[3]

Dhédin N, 1998, TRANSPLANTATION, V66, P616

[4] Lamivudine as initial treatment for chronic hepatitis B in the United States [J].

Dienstag, JL ;

Schiff, ER ;

Wright, TL ;

Perrillo, RP ;

Hann, HWL ;

Goodman, Z ;

Crowther, L ;

Condreay, LD ;

Woessner, M ;

Rubin, M ;

Brown, NA .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263

[5]

Endo T, 2000, Rinsho Ketsueki, V41, P322

[6] Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period [J].

Iwai, K ;

Tashima, M ;

Itoh, M ;

Okazaki, T ;

Yamamoto, K ;

Ohno, H ;

Marusawa, H ;

Ueda, Y ;

Nakamura, T ;

Chiba, T ;

Uchiyama, T .

BONE MARROW TRANSPLANTATION, 2000, 25 (01) :105-108

[7]

MARTIN BA, 1995, BONE MARROW TRANSPL, V15, P145

[8] Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen [J].

Mason, AL ;

Xu, LZ ;

Guo, LS ;

Kuhns, M ;

Perrillo, RP .

HEPATOLOGY, 1998, 27 (06) :1736-1742

[9] Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients [J].

Ohnishi, M ;

Kanda, Y ;

Takeuchi, T ;

Kim, SW ;

Hori, A ;

Niiya, H ;

Chizuka, A ;

Nakai, K ;

Saito, T ;

Makimoto, A ;

Tanosaki, R ;

Watanabe, T ;

Kobayashi, Y ;

Tobinai, K ;

Takaue, Y ;

Mineishi, S .

TRANSPLANTATION, 2002, 73 (05) :812-815

[10] Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation [J].

Sakamaki, H ;

Sato, Y ;

Mori, S ;

Ohashi, K ;

Tanikawa, S ;

Akiyama, H ;

Sasaki, T ;

Hiruma, K .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 74 (03) :342-346

← 1 2 →